Hereditary Angioedema
A rare inherited disorder causing recurrent, unpredictable episodes of severe swelling in the skin, gut, and airway, driven by uncontrolled activation of the bradykinin pathway.
- Genetic, lifelong condition
- Recurrent swelling episodes
- Modern targeted therapies available
- Airway attacks can be life-threatening
- Estimated Prevalence
- 1 in 50,000
- Inheritance Pattern
- Autosomal Dominant
- Typical Onset
- Childhood–Adolescence
- Advanced Therapies
- Targeted Prophylaxis
What Is Hereditary Angioedema?
Hereditary Angioedema (HAE) is a rare genetic disorder that causes sudden, recurrent episodes of swelling beneath the skin and in mucosal tissues, including the face, limbs, abdomen, and upper airway. Unlike allergic swelling, HAE attacks are not caused by histamine and do not respond to antihistamines or corticosteroids. They result from excess bradykinin, a peptide that increases vascular permeability, most often due to a deficiency or dysfunction of C1 esterase inhibitor (C1-INH).
Types of Hereditary Angioedema
HAE is classified by the underlying molecular defect, which helps guide testing and treatment selection.
Symptoms of Hereditary Angioedema
Attacks typically build over hours, can last 2–5 days, and vary widely in location and severity, even within the same person.
Causes and Risk Factors
HAE arises from mutations affecting C1 esterase inhibitor or, less commonly, other proteins in the bradykinin pathway, leading to uncontrolled vascular permeability.
How Hereditary Angioedema Is Diagnosed
Diagnosis relies on a combination of clinical history and specific laboratory testing, since complement levels can fluctuate and may need to be repeated.
Disease Severity Classification
HAE is not staged like cancer, but severity is generally classified by attack frequency, location, and impact on daily life to guide treatment intensity.
Standard Treatment Approach
Management of HAE rests on three pillars: on-demand treatment for acute attacks, short-term prophylaxis before triggering events, and long-term prophylaxis to reduce overall attack frequency.
Advanced and Emerging Therapies
HAE treatment has been transformed by therapies that directly target the bradykinin pathway, moving beyond older, less specific options.
Plasma Kallikrein Inhibitor
Subcutaneous Kallikrein-Targeted Therapy
Reduces bradykinin generation to lower long-term attack frequency.
C1-INH Replacement
Plasma-Derived or Recombinant C1-INH
Used for both on-demand treatment and long-term prophylaxis by restoring inhibitor activity.
Bradykinin B2 Receptor Antagonist
Targeted Receptor Blockade
Blocks the downstream effects of bradykinin during acute attacks.
Gene Silencing / Antisense Approaches
Investigational RNA-Targeted Therapies
Emerging approaches aiming to reduce prekallikrein or factor XII production for longer-lasting prevention.
Key Biomarkers and Laboratory Markers
Complement studies remain central to diagnosing and monitoring HAE.
When to Seek a Second Opinion
Because HAE is rare and easily misdiagnosed as allergic angioedema, a specialist second opinion can be valuable at several points in care.
Clinical Trials and Research
Outlook and Long-Term Prognosis
With modern targeted therapies, most people with HAE can achieve substantial control over attack frequency and severity, though the condition remains lifelong and requires ongoing management.
Supportive and Quality-of-Life Care
Living with HAE involves more than medication—ongoing education, planning, and emotional support help patients manage the unpredictability of the condition.
How CancerFax Helps You Explore Treatment Options
CancerFax can help you organize your medical records and connect with specialists experienced in managing Hereditary Angioedema and its advanced therapy options.
Get a free case reviewFrequently Asked Questions About Hereditary Angioedema
Hereditary Angioedema (HAE) is a rare genetic disorder that causes recurrent episodes of swelling in the skin, gut, and airway, caused by uncontrolled activity of bradykinin rather than an allergic reaction.
No. HAE swelling is driven by bradykinin, not histamine, so it does not respond to antihistamines, epinephrine, or corticosteroids the way allergic reactions do.
Most forms of HAE follow an autosomal dominant pattern, meaning a child of an affected parent has roughly a 50% chance of inheriting the condition, though new mutations can also occur.
Common triggers include physical trauma, dental or surgical procedures, infections, emotional stress, and hormonal changes such as pregnancy or estrogen-containing medications, although attacks can also occur with no identifiable trigger.
Diagnosis combines a detailed clinical history with blood tests measuring C4, C1-inhibitor levels, and C1-inhibitor function, sometimes supported by genetic testing.
There is currently no cure, but modern on-demand and prophylactic therapies allow many patients to achieve excellent control over attack frequency and severity.
Throat or airway swelling is a medical emergency. Use on-demand treatment as directed and seek immediate emergency care, since laryngeal attacks can progress to airway obstruction.
Many women with HAE have successful pregnancies, but treatment plans often need adjustment, since pregnancy and hormonal changes can affect attack frequency; close coordination with a specialist is recommended.
Yes. Newer therapies targeting plasma kallikrein and the bradykinin pathway have significantly expanded treatment options beyond older C1-inhibitor replacement and androgen-based therapies.
Yes. CancerFax can help you organize and send your medical reports for specialist review, coordinate a second opinion, and explore access to advanced HAE therapies, including international coordination where relevant.
Need Help Navigating Hereditary Angioedema Care?
Send your medical reports for review and let our team help you connect with specialists and explore advanced treatment options.